OT4B
Pre-clinicalCreated in 2017, OT4B aims to develop oxytocin as the first treatment for patients with Prader-Willi syndrome and to make it accessible as soon as possible to as many people as possible.
Founded
2007
Focus
Small Molecules
About
Created in 2017, OT4B aims to develop oxytocin as the first treatment for patients with Prader-Willi syndrome and to make it accessible as soon as possible to as many people as possible.
Company Info
TypePrivate
Founded2007
LocationParis, France
StagePre-clinical
Contact
SIMILAR COMPANIES
4P-Pharma
Phase 2 · Lille
Patheon
Pre-clinical · Lyon
ABL Diagnostics
Pre-clinical · Strasbourg
Acticor Biotech
Pre-clinical · Paris
Adjuvatis
Pre-clinical · Lyon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile